enGene Therapeutics News and Activities

enGene Therapeutics is a company listed under the stock ticker ENGN (CA).

Acquisition, funding and merger involving enGene Therapeutics.

• The new name of enGene is enGene Therapeutics. (posted on April 8 2026).

View the org chart displaying its 27 main executives

Most searched biographies at enGene Therapeutics

• Ron Cooper, Chief Executive Officer and Director
• Richard Glickman, Chairman of the Board
• Michael Heffernan, Director

Popular executive movements at enGene Therapeutics

• Hussein Sweiti has joined the company as Chief Medical Officer  (posted on October 1 2025).

Create your alert
to follow the executive moves at enGene Therapeutics.

enGene Therapeutics has 2,406 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
• NewLimit has just announced a $435 Million fundraising (posted on June 3 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Valerie Hanote - Non-Executive Director at Eurofins

Learn more about the Biotechnology industry

Press releases by enGene Therapeutics

• enGene - In the News
• enGene Holdings Inc. News powered by B2i Technologies - SmartWireenGene Holdings Inc. News powered by B2i Technologies - SmartWire
• enGene - Communiqués de presse
• enGene - Press Releases

Social media about enGene Therapeutics

• enGene Therapeutics on Wikipedia, Google News & Yahoo Finance
• enGene Therapeutics on LinkedIn, X (Twitter) & YouTube